Sugi Predict

Sugi Predict / Targets / KMT5B

KMT5B

Histone-lysine N-methyltransferase KMT5B · Q4FZB7 · KMT5B on Sugi Atlas →

2,008 patent compounds predicted against KMT5B, 1,474 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1613404 SCHEMBL1613404 0.81 2/20
SCHEMBL4963680 SCHEMBL4963680 0.80 2/20
SCHEMBL1147527 SCHEMBL1147527 0.78 2/20
SCHEMBL3706336 SCHEMBL3706336 0.78 2/20
SCHEMBL3708467 SCHEMBL3708467 0.78 2/20
SCHEMBL3711288 SCHEMBL3711288 0.78 2/20
SCHEMBL4811736 SCHEMBL4811736 0.78 2/20
SCHEMBL6861746 SCHEMBL6861746 0.78 2/20
SCHEMBL6861753 SCHEMBL6861753 0.78 2/20
SCHEMBL1147688 SCHEMBL1147688 0.76 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1876988) 0.76 2/20
SCHEMBL6865829 SCHEMBL6865829 0.76 2/20
SCHEMBL6865834 SCHEMBL6865834 0.76 2/20
SCHEMBL1147609 SCHEMBL1147609 0.74 2/20
SCHEMBL4810793 SCHEMBL4810793 0.71 2/20
SCHEMBL1147647 SCHEMBL1147647 0.71 2/20
SCHEMBL1550555 SCHEMBL1550555 0.71 2/20
SCHEMBL3711092 SCHEMBL3711092 0.70 2/20
SCHEMBL6866156 SCHEMBL6866156 0.70 2/20
SCHEMBL6866164 SCHEMBL6866164 0.70 2/20

Clinical trials — most relevant to KMT5B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma PHASE1ACTIVE_NOT_RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
The Danish TURNER Cryopreservation Study nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KMT5B binder may also engage these)

ProteinNameSimilarity
P0C2N5 — 1.000 P0C2N5 →
Q5RJX8 — 1.000 Q5RJX8 →
Q3U8K7 — 1.000 Q3U8K7 →
Q6KAQ7 — 0.999 Q6KAQ7 →
Q8C0I4 — 0.999 Q8C0I4 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.999 landscape →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.999 landscape →
Q5SPL2 — 0.998 Q5SPL2 →
Q5R7I3 — 0.998 Q5R7I3 →
Q9LS86 — 0.997 Q9LS86 →
Q2PFD7 — 0.997 Q2PFD7 →
Q6GP17 — 0.997 Q6GP17 →
Q52LR7 — 0.997 Q52LR7 →
A6QP06 — 0.997 A6QP06 →
Q08639 — 0.997 Q08639 →
Q99PI5 — 0.997 Q99PI5 →
Q8WML3 — 0.997 Q8WML3 →
Q9SB51 — 0.997 Q9SB51 →
Q8IYH5 — 0.997 Q8IYH5 →
Q6NN85 — 0.997 Q6NN85 →
Q1LVC2 — 0.997 Q1LVC2 →
Q499D0 — 0.997 Q499D0 →
Q28DE6 — 0.997 Q28DE6 →
Q3UG20 — 0.996 Q3UG20 →
Q9Z2U2 — 0.996 Q9Z2U2 →
Q5U3H2 — 0.996 Q5U3H2 →
P22199 — 0.996 P22199 →
A0JMK9 — 0.996 A0JMK9 →
Q64318 — 0.996 Q64318 →
Q9NQW6 — 0.996 Q9NQW6 →